Journal
STEM CELL RESEARCH & THERAPY
Volume 6, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13287-015-0233-8
Keywords
Potency assay; Immune response modulation; Mesenchymal stem/progenitor cells; T cells
Funding
- Anniversary Fund of the Oesterreichische Nationalbank (OeNB) [15941]
- German Ministry of Education and Research (BMBF) within the program Cell based Regenerative Medicine (START-MSC2) [01GN0939]
- Austrian Science Fund (FWF)
- Austrian Science Fund (Erwin Schroedinger Fellowship)
Ask authors/readers for more resources
The inherent immunomodulatory capacity of mesenchymal stem/progenitor cells (MSPCs) encouraged initiation of multiple clinical trials. Release criteria for therapeutic MSPCs cover identity, purity and safety but appropriate potency assessment is often missing. Reports on functional heterogeneity of MSPCs created additional uncertainty regarding donor and organ/source selection. We established a robust immunomodulation potency assay based on pooling responder leukocytes to minimize individual immune response variability. Comparing various MSPCs revealed significant potency inconsistency and generally diminished allo-immunosuppression compared to dose-dependent inhibition of mitogenesis. Gamma-irradiation to block unintended MSPC proliferation did not prohibit chondrogenesis and osteogenesis in vivo, indicating the need for alternative safety strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available